Psilocybin for Eating Disorders: Anorexia and Binge Eating

The Short Answer

Eating disorders — particularly anorexia nervosa — are characterized by extreme cognitive rigidity: rigid rules about food, rigid body image distortions, and rigid behavioral patterns that persist despite severe health consequences. Psilocybin's primary therapeutic mechanism — disrupting rigid neural patterns and increasing cognitive flexibility — is directly relevant to eating disorder treatment. A 2023 pilot study at Johns Hopkins found psilocybin-assisted therapy produced significant improvements in anorexia symptoms in all 10 participants [Peck et al., 2023].

Why Eating Disorders Are So Treatment-Resistant

Anorexia nervosa (AN) has the highest mortality rate of any psychiatric condition — approximately 10% of patients die from the illness or its complications [Koning, 2024]. Standard treatments, such as Cognitive Behavioral Therapy (CBT) and nutritional rehabilitation, often have limited effectiveness, especially for severe or long-standing cases [Calder, 2023]. The core problem lies in the profound cognitive rigidity associated with AN, where eating disorder thoughts and behaviors become deeply entrenched neural patterns that are highly resistant to change through conventional therapeutic approaches [Koning, 2024]. This rigidity manifests as an inflexible adherence to dietary rules, distorted body image, and compulsive behaviors around food and weight, making recovery exceptionally challenging [UCSF Clinical Trials, NCT06399263].

The Neurobiological Basis of Rigidity

Psilocybin's ability to promote neuroplasticity is a key factor in its therapeutic potential for eating disorders. For more on this, see our article on Psilocybin and Neuroplasticity.

Emerging research suggests that eating disorders involve alterations in brain circuits related to reward, habit formation, and cognitive control [Steward, 2024]. These alterations contribute to the persistent and often intractable nature of the illness. Psilocybin, a psychedelic compound, is believed to exert its therapeutic effects by modulating serotonin 5-HT2A receptors, leading to increased neuroplasticity and a temporary disruption of these rigid neural patterns [Koning, 2024]. This "reset" or "rewiring" effect may provide a window of opportunity for patients to adopt new, healthier perspectives and behaviors, facilitating recovery in a way that traditional therapies struggle to achieve [Peck et al., 2023].

The Johns Hopkins Pilot Study

A landmark 2023 open-label pilot study at Johns Hopkins University enrolled 10 adults with anorexia nervosa to evaluate the safety and efficacy of psilocybin-assisted therapy [Peck et al., 2023]. The study involved two psilocybin sessions accompanied by extensive psychotherapy. The results were highly encouraging:

• All 10 participants showed improvements in eating disorder symptoms.
• Significant reductions were observed in eating disorder cognitions, such as rigid food rules and body image distortion.
• Participants reported improvements in quality of life and psychological flexibility.
• Importantly, there were no serious adverse events, suggesting that the treatment is safe and tolerable for this population [Peck et al., 2023].

These findings, while preliminary, highlight the potential of psilocybin to address the core psychological mechanisms driving anorexia nervosa. The study's success has paved the way for larger, more rigorous clinical trials to further investigate this novel approach [ClinicalTrials.gov, NCT04661514].

Binge Eating Disorder

Binge eating disorder (BED) involves compulsive eating patterns that share characteristics with addiction — impulsive behavior driven by rigid neural patterns [Psychiatric Times, 2022]. Individuals with BED often experience a loss of control during binge episodes, followed by feelings of guilt and shame. Psilocybin's effectiveness in treating various forms of addiction, such as alcohol and tobacco dependence, suggests it may also hold promise for BED [Psychiatric Times, 2022]. By disrupting the habitual neural pathways associated with compulsive eating and enhancing cognitive flexibility, psilocybin could help individuals with BED regain control over their eating behaviors and develop healthier coping mechanisms [Koning, 2024].

Exploring the Connection Between Addiction and BED

The similarities between BED and substance use disorders are increasingly recognized in the scientific community. Both conditions involve dysregulation in the brain's reward system and difficulties with impulse control [Steward, 2024]. Psilocybin's ability to modulate these systems and promote neuroplasticity makes it a compelling candidate for treating BED. Ongoing research is exploring how psilocybin-assisted therapy can be tailored to address the specific psychological and behavioral challenges associated with binge eating [Psychiatric Times, 2022].

The Role of Neuroplasticity in Recovery

Neuroplasticity, the brain's ability to reorganize itself by forming new neural connections, is a crucial factor in recovering from eating disorders. Conditions like anorexia and binge eating disorder are characterized by maladaptive neural pathways that reinforce harmful behaviors and thought patterns [Koning, 2024]. Psilocybin has been shown to rapidly and robustly promote neuroplasticity, potentially allowing the brain to "unlearn" these maladaptive patterns and establish healthier ones [Peck et al., 2023]. This enhanced plasticity, combined with the insights gained during the psychedelic experience and the support of psychotherapy, can facilitate profound and lasting changes in individuals struggling with eating disorders [Calder, 2023].

The Importance of Set and Setting

In the context of psilocybin-assisted therapy, "set" (the individual's mindset, expectations, and emotional state) and "setting" (the physical and social environment) are critical determinants of the therapeutic outcome [Peck et al., 2023]. Clinical trials carefully control these variables to ensure a safe and supportive experience. Participants undergo extensive preparation before the psilocybin sessions and receive integration therapy afterward to help them process and apply the insights gained during the experience [Calder, 2023]. This comprehensive approach is essential for maximizing the therapeutic benefits and minimizing potential risks.

Future Directions and Ongoing Research

The promising results from early pilot studies have spurred a wave of new research into psilocybin for eating disorders. Several clinical trials are currently underway or in the planning stages, aiming to evaluate the efficacy and safety of this treatment in larger and more diverse populations [ClinicalTrials.gov, NCT07169747]. These studies will also explore optimal dosing strategies, the role of different psychotherapeutic modalities, and the long-term durability of the treatment effects [UCSF Clinical Trials, NCT06399263]. As the research progresses, psilocybin-assisted therapy may emerge as a transformative treatment option for individuals who have not found relief through conventional approaches.

Shrooomz and the Future of Functional Mushrooms

While psilocybin research is advancing rapidly, it's important to note that non-psychoactive functional mushrooms also offer significant health benefits. At Happy Shrooomz, we are dedicated to providing high-quality functional mushroom products that support overall well-being. For example, Lion's Mane has been studied for its potential to support cognitive function and brain health, which can be beneficial for individuals seeking to improve their mental clarity and focus.

The Neurobiological Mechanisms of Psilocybin in Eating Disorders

Psilocybin, the psychoactive compound found in certain mushrooms, primarily acts on the brain's serotonin 5-HT2A receptors. This interaction is believed to be central to its therapeutic effects, particularly its ability to induce states of altered consciousness and promote neuroplasticity [Koning, 2024]. In the context of eating disorders, this neuroplastic effect is crucial. Eating disorders are often characterized by deeply ingrained, maladaptive thought patterns and behaviors that are resistant to change. Psilocybin's ability to transiently disrupt these rigid neural circuits can create a window of opportunity for therapeutic intervention, allowing individuals to re-evaluate their relationship with food, body image, and self-worth [Peck et al., 2023].

Serotonin System Dysregulation

Research indicates that individuals with eating disorders often exhibit dysregulation in their serotonin systems, which play a vital role in mood, appetite, and impulse control [Steward, 2024]. Psilocybin's agonistic action at 5-HT2A receptors can help normalize these dysregulations, leading to improvements in mood and a reduction in obsessive-compulsive behaviors associated with eating disorders. This normalization can contribute to increased emotional regulation and a greater sense of well-being, which are essential for long-term recovery [Calder, 2023].

Default Mode Network (DMN) and Cognitive Rigidity

The Default Mode Network (DMN) is a brain network active during self-referential thought, rumination, and planning. In eating disorders, the DMN is often hyperactive, contributing to rigid thinking, self-criticism, and obsessive preoccupation with food and body weight [Koning, 2024]. Psilocybin has been shown to transiently reduce activity and connectivity within the DMN, leading to a dissolution of ego and a more expansive, less self-focused perspective [Carhart-Harris et al., 2014]. This temporary disruption can help individuals break free from entrenched negative thought loops and gain new insights into their condition, fostering a more flexible and adaptive mindset [Peck et al., 2023]. For further reading on how psilocybin affects brain function, consider exploring our article on Psilocybin Neuroplasticity: How Mushrooms Rewire the Brain.

Detailed Look at the Johns Hopkins Pilot Study and Other Research

The 2023 Johns Hopkins open-label pilot study, led by Peck and colleagues, provided compelling initial evidence for psilocybin-assisted therapy in anorexia nervosa [Peck et al., 2023]. The study design involved careful screening of participants, followed by preparatory psychotherapy sessions. Participants then received a single dose of psilocybin in a supportive clinical setting, with therapists present throughout the experience. This was followed by integration therapy, where participants processed their experiences and worked to incorporate insights into their daily lives. The observed improvements in eating disorder symptoms, cognitions, and psychological flexibility were sustained at follow-up, suggesting a durable effect [Peck et al., 2023].

Beyond Anorexia: Psilocybin for Binge Eating Disorder

While much of the initial research has focused on anorexia nervosa due to its severity and high mortality rate, the therapeutic potential of psilocybin extends to other eating disorders, particularly binge eating disorder (BED). BED shares several underlying psychological and neurobiological features with addiction, including impulsivity, compulsive behaviors, and dysregulation of reward pathways [Psychiatric Times, 2022]. Psilocybin's efficacy in treating substance use disorders, such as alcohol and nicotine dependence, provides a strong rationale for its investigation in BED [Johnson et al., 2014; Bogenschutz et al., 2015]. By targeting the neural circuits involved in habit formation and reward, psilocybin could help individuals with BED disrupt compulsive eating patterns and develop healthier relationships with food. Ongoing clinical trials are actively exploring these connections [ClinicalTrials.gov, NCT07169747].

The Importance of a Holistic Approach

It is crucial to emphasize that psilocybin is not a standalone treatment. Its effectiveness is maximized when integrated into a comprehensive therapeutic framework that includes psychological support, nutritional guidance, and ongoing aftercare [Calder, 2023]. The psychedelic experience itself can be profound and challenging, requiring skilled therapists to guide individuals through difficult emotions and facilitate meaningful insights. The integration phase, where these insights are translated into practical changes in daily life, is equally vital for sustained recovery. This holistic approach ensures that individuals receive the necessary support to navigate the complexities of eating disorder recovery.

Frequently Asked Questions (FAQ)

Is psilocybin a cure for anorexia?

For information on how psilocybin can help with related conditions, explore our article on Microdosing Mushrooms for Depression.

No, psilocybin is not a "cure" for anorexia or any other eating disorder. It is a tool that, when combined with psychotherapy, can help individuals break free from rigid thought patterns and develop healthier behaviors. Recovery is a complex and ongoing process that requires comprehensive support [Peck et al., 2023].

How does psilocybin differ from traditional antidepressants for eating disorders?

For a detailed comparison, read our analysis of Psilocybin vs. SSRIs.

Traditional antidepressants, such as SSRIs, often have limited efficacy in treating anorexia and can take weeks to show effects. Psilocybin, on the other hand, appears to act more rapidly by promoting neuroplasticity and disrupting entrenched neural circuits, offering a different mechanism of action that may be more effective for some individuals [Koning, 2024].

Are there risks associated with psilocybin therapy for eating disorders?

While early studies suggest that psilocybin is generally safe and well-tolerated in controlled clinical settings, it is not without risks. Potential side effects include transient anxiety, nausea, and headaches. The therapy must be administered by trained professionals in a supportive environment to minimize risks and maximize benefits [Peck et al., 2023].

Can I use psilocybin on my own to treat my eating disorder?

It is strongly advised against using psilocybin outside of a clinical or therapeutic setting for the treatment of eating disorders. The therapeutic effects depend heavily on the preparation, support, and integration provided by trained professionals. Self-medication can be unpredictable and potentially harmful [Calder, 2023].

See the protocol → This article is for informational purposes only and does not constitute medical advice.

References

• Calder, A., et al. (2023). REVIEW Psychedelics in the treatment of eating disorders. ScienceDirect.
• Carhart-Harris, R. L., et al. (2014). The default mode network in psilocybin-assisted psychotherapy. PNAS.
• ClinicalTrials.gov. (NCT04661514). Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy.
• ClinicalTrials.gov. (NCT07169747). Study of Psilocybin for Anorexia in Young Adults.
• Johnson, M. W., et al. (2014). Psilocybin-assisted treatment for nicotine addiction: A randomized, double-blind, placebo-controlled pilot study. Journal of Psychopharmacology.
• Koning, E., et al. (2024). Psilocybin-assisted psychotherapy as a potential treatment for eating disorders. PMC.
• Peck, S. K., et al. (2023). Psilocybin therapy for females with anorexia nervosa. Nature Medicine.
• Psychiatric Times. (2022). Psychedelics for the Treatment of Binge Eating Disorder in Males.
• Steward, T. (2024). Endocrinology-informed neuroimaging in eating disorders: GLP1, orexins, and psilocybin. Trends in Molecular Medicine.
• UCSF Clinical Trials. (NCT06399263). Study of Psilocybin for Anorexia in Young Adults.

Ready to experience the difference?

Shop Secret Shrooomz →